Metal in Tablet Prompts Recall

Metal found in a tablet has prompted Rubicon Research Private Limited to recall 11,664 bottles of metoprolol tartrate, according to the June 5, 2024, US Food and Drug Administration (FDA) Enforcement Report.

The recall affects metoprolol tartrate tablets, 25 mg, in 1000-count bottles (NDC 52817-360-00), from lot 231037H1 (Exp. 6/27). The tablets were manufactured by Rubicon Research Private Limited, Ambernath, India, and distributed throughout the United States by TruPharma, Tampa, Florida.

Rubicon Research Private Limited voluntarily initiated the recall on May 6, 2024. The FDA designated it Class II on May 29, 2024. The designation communicates that use of the recalled drug may cause temporary or medically reversible adverse health consequences. A remote possibility of serious harm also exists.

Metoprolol is a prescription beta blocker with indications for hypertension, angina pectoris, and myocardial infarction.